Free Trial

Aerovate Therapeutics (AVTE) Competitors

Aerovate Therapeutics logo
$9.51 +0.70 (+7.95%)
As of 07/17/2025

AVTE vs. ELVN, GPCR, CDTX, ARDX, PRAX, PROK, COLL, AKBA, AMPH, and RCUS

Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Cidara Therapeutics (CDTX), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

Aerovate Therapeutics vs. Its Competitors

Aerovate Therapeutics (NASDAQ:AVTE) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

95.1% of Enliven Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 81.82%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-5.59
Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.80

Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Enliven Therapeutics' return on equity of -31.84% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Enliven Therapeutics N/A -31.84%-30.09%

In the previous week, Enliven Therapeutics had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Enliven Therapeutics and 0 mentions for Aerovate Therapeutics. Enliven Therapeutics' average media sentiment score of 0.71 beat Aerovate Therapeutics' score of 0.00 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Enliven Therapeutics Positive

Summary

Enliven Therapeutics beats Aerovate Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTE vs. The Competition

MetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$275.65M$816.22M$5.54B$9.41B
Dividend YieldN/A4.84%3.75%4.03%
P/E Ratio-3.181.2021.0120.09
Price / SalesN/A25.49433.8199.01
Price / CashN/A19.5636.1658.27
Price / Book2.406.878.125.65
Net Income-$75.52M-$4.17M$3.25B$257.91M
7 Day Performance-9.60%0.03%0.97%2.09%
1 Month Performance14.72%2.12%7.36%11.13%
1 Year Performance-85.07%2.14%31.31%18.40%

Aerovate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTE
Aerovate Therapeutics
N/A$9.51
+7.9%
N/A-86.7%$275.65MN/A-3.1820High Trading Volume
ELVN
Enliven Therapeutics
2.8636 of 5 stars
$23.00
+2.4%
$41.20
+79.1%
-1.8%$1.13BN/A-11.9850News Coverage
GPCR
Structure Therapeutics
2.9436 of 5 stars
$19.57
+2.9%
$76.17
+289.2%
-49.1%$1.12BN/A-22.49136
CDTX
Cidara Therapeutics
3.6939 of 5 stars
$55.32
+9.5%
$57.29
+3.6%
+331.6%$1.12B$1.27M-1.8890Positive News
High Trading Volume
ARDX
Ardelyx
4.1637 of 5 stars
$4.61
+2.7%
$10.89
+136.2%
-21.4%$1.10B$333.61M-20.9590Analyst Revision
PRAX
Praxis Precision Medicines
2.4592 of 5 stars
$53.60
+6.1%
$94.11
+75.6%
-0.3%$1.09B$8.55M-5.00110News Coverage
Analyst Forecast
Analyst Revision
PROK
ProKidney
3.4049 of 5 stars
$3.69
-18.7%
$5.67
+53.6%
+53.0%$1.08B$306K-6.153Analyst Forecast
Gap Up
High Trading Volume
COLL
Collegium Pharmaceutical
4.4186 of 5 stars
$32.83
+1.0%
$43.75
+33.3%
+1.0%$1.05B$631.45M26.91210Positive News
AKBA
Akebia Therapeutics
3.7148 of 5 stars
$3.97
+1.0%
$6.75
+70.0%
+175.2%$1.04B$160.18M-18.90430
AMPH
Amphastar Pharmaceuticals
4.3171 of 5 stars
$21.95
+1.3%
$32.33
+47.3%
-45.0%$1.03B$731.97M7.952,028
RCUS
Arcus Biosciences
2.3406 of 5 stars
$9.66
+3.5%
$21.29
+120.5%
-39.0%$1.02B$258M-2.30500

Related Companies and Tools


This page (NASDAQ:AVTE) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners